SMART IMMUNE

Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The company aims to radically improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is already in Phase I/II clinical trials, in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The Company is headquartered in Paris, France, at Paris Biotech Santé.